

Island Pharmaceuticals Limited
Appendix 4E
Preliminary final report

1. Company details

Name of entity:	Island Pharmaceuticals Limited
ABN:	48 641 183 842
Reporting period:	For the year ended 30 June 2024
Previous period:	For the year ended 30 June 2023

2. Results for announcement to the market

			\$
Revenues from ordinary activities	up	11344.1% to	1,266,289
Loss from ordinary activities after tax attributable to the owners of Island Pharmaceuticals Limited	up	1.2% to	(2,864,318)
Loss for the year attributable to the owners of Island Pharmaceuticals Limited	up	1.2% to	(2,864,318)

Dividends

There were no dividends paid, recommended or declared during the current financial period.

Comments

The loss for the Group after providing for income tax amounted to \$2,864,318 (30 June 2023: \$2,830,449).

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	<u>1.20</u>	<u>2.20</u>

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous period

There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements have been audited and an unmodified opinion has been issued.


11. Attachments

Details of attachments (if any):

The Annual Report of Island Pharmaceuticals Limited for the year ended 30 June 2024 is attached.

12. Signed

Signed



Paul MacLeman
Executive Chairman

Date: 29 August 2024